Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures sink as AI doubts resurface, oil jumps
- Oil jumps on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 --0%
Revenue Growth %: +37.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SK Hynix could join the Nasdaq 100 if it expands its ADR float: Goldman
- BofA Securities on CoreWeave (CRWV): 'Capex outlook and funding needs remain key'
- CAVA Group Inc (CAVA) PT Lowered to $85 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
